Fibrosis and Cirrhosis Reversibility: Clinical Features and Implications

Clinics in Liver Disease

Volumn 12, Issue 4, 2008, Pages 901-913

  Pinzani, Massimo ^a   Vizzutti, Francesco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antifibrotic therapy; Chronic liver disease; Cirrhosis; Fibrosis

Indexed keywords

ANTIFIBROTIC AGENT; ANTIVIRUS AGENT;

ANGIOGENESIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DISEASE COURSE; FIBROGENESIS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PARENCHYMA; MOLECULAR MECHANICS; REMISSION; REVIEW;

CHRONIC DISEASE; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; NEOVASCULARIZATION, PATHOLOGIC; PORTAL PRESSURE; PORTAL VEIN; RECOVERY OF FUNCTION; VENOUS PRESSURE;

EID: 54549089861     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.07.006     Document Type: Review

References (79)

1. Friedman S.L., and Bansal M.B. Reversal of hepatic fibrosis-fact or fantasy?. Hepatology 43 (2006) S82-S88
2. Anthony P.P., Ishak K.G., Nayak N.C., et al. The morphology of cirrhosis. Working group sponsored by the World Health Organization. J Clin Pathol 31 (1978) 395-414
3. Millward-Sadler G.H., Hanh E.G., and Wright R. Cirrhosis: an appraisal. In: Wright R., Millward-Sadler G.H., and Alberti K.G.M.M. (Eds). Liver and biliary disease. 2nd edition (1985), Baillière Tindall WB Saunders, London 821-860
4. Rappaport A.M., McPhee P.J., Fisher M.M., et al. The scarring of the liver acini (cirrhosis). Tridimensional and microcirculatory considerations. Virchows Arch A Pathol Anat Histopathol 402 (1983) 107-137
5. Reichen J., Egger B., Ohara N., et al. Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis. J Clin Invest 82 (1988) 2069-2076
6. Wanless I.R., Wong F., Blendis L.M., et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21 (1995) 1238-1247
7. Garcia-Monzon C., Sanchez-Madrid F., Garcia-Buey L., et al. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 108 (1995) 231-241
8. Medina J., Arroyo A.G., Sanchez-Madrid F., et al. Angiogenesis in chronic inflammatory liver disease. Hepatology 39 (2004) 1185-1195
9. Medina J., Sanz-Cameno P., Garcia-Buey L., et al. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol 42 (2005) 124-131
10. Pinzani M., and Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 36 (2004) 231-242
11. Pinzani M., and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liv Dis 21 (2001) 397-416
12. Shackel N.A., McGuinnes P., Abbott C.A., et al. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic gene expression. Am J Pathol 160 (2002) 642-654
13. Shackel N.A., McGuinnes P., Abbott C.A., et al. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 49 (2001) 567-576
14. Hoofring A., Boitnott J., and Torbenson M. Three-dimensional reconstruction of hepatic bridging fibrosis in chronic hepatitis C viral infection. J Hepatol 39 (2003) 738-741
15. DeLeve L.D. Hepatic microvasculature in liver injury. Semin Liver Dis 27 (2007) 390-400
16. Rosmorduc O., Wendum D., Corpechot C., et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary fibrosis. Am J Pathol 155 (1999) 1065-1073
17. Onori P., Morini S., Franchitto A., et al. Hepatic microvascular features in experimental cirrhosis: a structural and morphometrical study in CCl4-treated rats. J Hepatol 33 (2000) 555-563
18. Jin Y.L., Enzan H., Kuroda N., et al. Vascularization in tissue remodeling after rat hepatic necrosis induced by dimethylnitrosamine. Med Mol Morphol 39 (2006) 33-43
19. Corpechot C., Barbu V., Wendum D., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35 (2002) 1010-1021
20. Nakamura T., Torimura T., Sakamoto M., et al. Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model. Gastroenterology 133 (2007) 91-107
21. Ankoma-Sey V., Matli M., Chang K.B., et al. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 17 (1998) 115-121
22. Wang Y.Q., Luk J.M., Ikeda K., et al. Regulatory role of vHL/HIF-1α in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 317 (2004) 358-362
23. Lee J.S., Semela D., Iredale J., et al. Sinusoidal remodeling and angiogenesis: a new function for the liver specific pericyte?. Hepatology 45 (2007) 817-825
24. Novo E., Cannito S., Zamara E., et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 170 (2007) 1942-1953
25. Aleffi S., Petrai I., Bertolani C., et al. Upregulation of proinflammatory and proangiogenic cytookines by leptin in human hepatic stellate cells. Hepatology 42 (2005) 1339-1348
26. Tugues S., Fernandez-Varo G., Muñoz-Luque J., et al. Antiangiogenic treatment with Sunitinib ameliorated inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46 (2007) 1919-1926
27. Quinn P.S., and Higginson J. Reversible and irreversible changes in experimental cirrhosis. Am J Pathol 47 (1965) 353-369
28. Perez-Tamayo R. Cirrhosis of the liver: a reversible disease?. Pathol Annu 14 Pt2 (1979) 183-213
29. Shiratori Y., Imazeki F., Moriyama M., et al. Histological improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132 (2000) 517-524
30. Kweon Y.O., Goodman Z.D., Dienstag J.L., et al. Decreasing fibrogenesis: an immunoistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 35 (2001) 749-755
31. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
32. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
33. Farci P., Roskams T., Chessa L., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126 (2004) 1740-1749
34. Serpaggi J., Carnot F., Nalpas B., et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 37 (2006) 1519-1526
35. Hui C.K., Leung N., Shek T.W., et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 46 (2007) 690-698
36. Dufour J.F., DeLellis R., and Kaplan M.M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127 (1997) 981-985
37. Wakim-Fleming J., and Mullen K.D. Long-term management of alcoholic liver disease. Clin Liver Dis 9 (2005) 135-149
38. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
39. Kral J.G., Thung S.N., Biron S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis, and cirrhosis. Surgery 135 (2004) 48-58
40. Desmet V.J., and Roskams T. Reversal of cirrhosis: evidence based medicine?. Gastroenterology 125 (2003) 629-630
41. Desmet V.J., and Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 40 (2004) 860-867
42. Wanless I.R., Nakashima E., and Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 124 (2000) 1599-1607
43. Desmet V.J. Milestones in liver disease. Scoring chronic hepatitis. J Hepatol 38 (2003) 382-386
44. Popper H. What are the major types of hepatic cirrhosis?. In: Ingelfinger F., Relman A., and Finland M. (Eds). Controversies in internal medicine (1966), WB Saunders, Philadelphia 233-243
45. Fauerholdt L., Schlichting P., Christensen E., et al. The Copenhagen study group for liver disease. Conversion of micronodular into macronodular cirrhosis. Hepatology 3 (1983) 928-931
46. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
47. Ricard-Blum S., Bresson-Hadni S., Vuitton D.A., et al. Hydroxypyridinium collagen cross-links in human liver fibrosis: study of alveolar echinococcosis. Hepatology 15 (1992) 599-602
48. Hayasaka A., Ilda S., Suzuki N., et al. Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis. J Hepatol 24 (1996) 692-698
49. Issa R., Zhou X., Constandinou C.M., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126 (2004) 1795-1808
50. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 (2005) 209-218
51. Iredale J.P. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 21 (2001) 427-436
52. Iredale J.P., Benyon R.C., Pickering J., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102 (1998) 538-549
53. Issa R., Williams E., Trim N., et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 (2001) 548-557
54. Issa R., Zhou X., Trim N., et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 17 (2003) 47-49
55. Novo E., Marra F., Zamara E., et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 55 (2006) 1174-1182
56. Milani S., Herbst H., Schuppan D., et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 144 (1994) 528-537
57. Duffield J.S., Forbes S.J., Constandinou C.M., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115 (2005) 56-65
58. Sakaida I., Terai S., Yamamoto N., et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 40 (2004) 1304-1311
59. Terai S., Ishikawa T., Omori K., et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 24 (2006) 2292-2298
60. Higashiyama R., Inagaki Y., Hong Y.Y., et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 45 (2007) 213-222
61. Russo F.P., Kallis Y.N., Alison M.R., et al. Bone marrow cells in the liver: diverse cells, diverse effects. Hepatology 46 (2007) 604-605
62. Pinzani M., Vizzutti M., Arena U., et al. Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 95-106
63. Pinzani M., Rombouts K., and Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 (2005) S22-S36
64. Pinzani M., Milani S., Herbst H., et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 148 (1996) 785-800
65. Wagner S., Breyholz H.J., Faust A., et al. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem 13 (2006) 2819-2838
66. Seef L.B., and Lie B.A. Is cirrhosis an inevitable consequence of chronic hepatitis C infection?. Clin Gastroenterol Hepatol 3 (2005) 840-842
67. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
68. Goodman Z.D., Becker R.L., Pockros P.J., et al. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 45 (2007) 886-894
69. Bosch J., Garcia-Pagan J.C., Berzigotti A., et al. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis 26 (2006) 348-362
70. Garcia-Tsao G., Groszmann R.J., Fisher R.L., et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 5 (1985) 419-424
71. Nagula S., Jain D., Groszmann R.J., et al. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 44 (2006) 111-117
72. Rincon D., Ripoll C., Lo Iacono O., et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 101 (2006) 2269-2274
73. Roberts S., Gordon A., McLean C., et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 5 (2007) 932-937
74. Carrión J.A., Navasa M., García-Retortillo M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 132 (2007) 1746-1756
75. Veldt B.J., Heathcote E.J., Wedemeyer H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147 (2007) 677-684
76. Fontana R.J., Goodman Z.D., Dienstag J., et al. Relationship of serum markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 47 (2008) 789-798
77. Vizzutti F., Arena U., Romanelli R.G., et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 45 (2007) 1290-1297
78. Foucher J., Chanteloup E., Vergnion J., et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55 (2006) 403-438
79. Ripoll C., Banares R., Rincon R., et al. Influence of hepatic venous gradient on the prediction of survival of patients with cirrhosis in the MELD era. Hepatology 42 (2005) 793-801